Cargando…

Healthcare resources and costs associated with nonvalvular atrial fibrillation in Spain: apixaban versus acenocoumarol

AIM: Healthcare resources usage and costs associated to nonvalvular atrial fibrillation (NVAF) were analyzed in Spain. METHODS: This is an observational and retrospective study on patients with NVAF who started their treatment with apixaban or acenocoumarol between 1 January 2015 and 31 December 201...

Descripción completa

Detalles Bibliográficos
Autores principales:	Colet, Josep Comín, Mainar, Antoni Sicras, Salazar-Mendiguchía, Joel, del Campo Alonso, María Isabel, Echeto, Ainara, Larena, David Vilanova, Sánchez, Olga Delgado
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Becaris Publishing Ltd 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508311/ https://www.ncbi.nlm.nih.gov/pubmed/37489950 http://dx.doi.org/10.57264/cer-2023-0007

Ejemplares similares

RWD82 Influence of the COVID-19 Pandemic on Patients Receiving Oral Anticoagulants for the Treatment of Non-Valvular Atrial Fibrillation
por: Comin-Colet, J, et al.
Publicado: (2022)

Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation
por: Cirincione, Brenda, et al.
Publicado: (2018)

Laboratory Assessment of the Anticoagulant Activity of Apixaban in Patients With Nonvalvular Atrial Fibrillation
por: Kyriakou, Elias, et al.
Publicado: (2018)

Future projections of opioid use and cost in patients with chronic osteoarthritis pain in Spain
por: Rejas-Gutierrez, Javier, et al.
Publicado: (2021)

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
por: Yao, Xiaoxi, et al.
Publicado: (2016)

Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2018)

Spontaneous Spinal Epidural Hematoma in a Patient on Apixaban for Nonvalvular Atrial Fibrillation
por: El Alayli, Ahmad, et al.
Publicado: (2020)

Apixaban Concentrations in Routine Clinical Care of Older Adults With Nonvalvular Atrial Fibrillation
por: Thomas, Alveena, et al.
Publicado: (2022)

Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation
por: Martinez, Brandon K., et al.
Publicado: (2018)

Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation
por: Brown, Joshua D., et al.
Publicado: (2016)

Impact of COPD Exacerbations and Burden of Disease in Spain: AVOIDEX Study
por: Soler-Cataluña, Juan José, et al.
Publicado: (2023)

Low Performance of a Clinical-Genetic Model in the Estimation of Time in Therapeutic Range in Acenocoumarol-Adherent Patients with Nonvalvular Atrial Fibrillation: The Quality of Anticoagulation Challenge
por: Wasniewski, Samantha, et al.
Publicado: (2018)

Patient satisfaction after switching from warfarin to apixaban in patients with nonvalvular atrial fibrillation: AGAIN study
por: Koretsune, Yukihiro, et al.
Publicado: (2017)

Impact on healthcare resource utilization of multiple sclerosis in Spain
por: Sicras-Mainar, Antoni, et al.
Publicado: (2017)

Cost-effectiveness Analysis of Rivaroxaban versus Acenocoumarol in the Prevention of Stroke in Patients with Non-valvular Atrial Fibrillation in Spain
por: Rubio-Terrés, Carlos, et al.
Publicado: (2016)

Severe Atopic Dermatitis In Spain: A Real-Life Observational Study
por: Sicras-Mainar, Antoni, et al.
Publicado: (2019)

Comparative effectiveness and costs of generic and brand-name gabapentin and venlafaxine in patients with neuropathic pain or generalized anxiety disorder in Spain
por: Sicras-Mainar, Antoni, et al.
Publicado: (2015)

Comorbidity and metabolic syndrome in patients with multiple sclerosis from Asturias and Catalonia, Spain
por: Sicras-Mainar, Antoni, et al.
Publicado: (2017)

Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups
por: Gómez-Outes, Antonio, et al.
Publicado: (2013)

Apixaban in Comparison to Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Observational Studies
por: Siddiqui, Muhammad U., et al.
Publicado: (2019)

Warfarin vs. apixaban in nonvalvular atrial fibrillation, and analysis by concomitant antiarrhythmic medication use: A national retrospective study
por: Wanat, Matthew A., et al.
Publicado: (2019)

A Systematic Review of Network Meta-Analyses and Real-World Evidence Comparing Apixaban and Rivaroxaban in Nonvalvular Atrial Fibrillation
por: Hill, Nathan R., et al.
Publicado: (2020)

Acenocoumarol’s pharmacokinetic: linear or not?
por: Kumar, Parveen, et al.
Publicado: (2019)

Safety and effectiveness of apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: A regulatory postmarketing surveillance, the STANDARD study
por: Inoue, Hiroshi, et al.
Publicado: (2019)

Appropriateness of rivaroxaban and apixaban dosing in hospitalized patients with a newly diagnosed nonvalvular atrial fibrillation at a single tertiary hospital
por: Alshibani, Mohannad
Publicado: (2023)

Sick Leave and Costs in Active Workers with Chronic Osteoarthritis Pain in Spain: Outcomes of the OPIOIDS Real World Study
por: Sicras-Mainar, Antoni, et al.
Publicado: (2022)

Safety and Effectiveness of Apixaban Versus Warfarin in Japanese Patients with Nonvalvular Atrial Fibrillation Stratified by Renal Function: A Retrospective Cohort Study
por: Morimoto, Takeshi, et al.
Publicado: (2023)

Effectiveness and safety of dabigatran versus acenocoumarol in ‘real-world’ patients with atrial fibrillation
por: Korenstra, Jennie, et al.
Publicado: (2016)

Clinical Consequences of the Overuse of Short-Acting β2-Adrenergic Agonists (SABA) in the Treatment of Asthma in Spain: The SABINA Study
por: Molina, Jesús, et al.
Publicado: (2023)

Achieving Lower LDL-C Levels After a Recent Myocardial Infarction Might Be Associated with Lower Healthcare Resource Use and Costs in Spain
por: Escobar-Cervantes, Carlos, et al.
Publicado: (2022)

Off-label reduced-dose apixaban does not reduce hemorrhagic risk in Taiwanese patients with nonvalvular atrial fibrillation: A retrospective, observational study
por: Chen, I-Chih, et al.
Publicado: (2021)

Using primary care data to assess comparative effectiveness and safety of apixaban and rivaroxaban in patients with nonvalvular atrial fibrillation in the UK: an observational cohort study
por: Jaksa, Ashley, et al.
Publicado: (2022)

Apixaban versus other anticoagulants in patients with nonvalvular fibrillation: a comparison of all-cause and event-related costs in real-life setting in France
por: Belhassen, Manon, et al.
Publicado: (2022)

Health outcomes and costs in patients with osteoarthritis and chronic pain treated with opioids in Spain: the OPIOIDS real-world study
por: Sicras-Mainar, Antoni, et al.
Publicado: (2020)

Clinical and economic consequences of ozenoxacin vs. other topical antibiotics for the treatment of impetigo: a real-life study in Spain
por: Rodríguez-Quintosa, Jaime, et al.
Publicado: (2022)

Acenocoumarol: Lack of efficacy: case report
Publicado: (2022)

Retrospective epidemiological study for the characterization of community- acquired pneumonia and pneumococcal pneumonia in adults in a well-defined area of Badalona (Barcelona, Spain)
por: Sicras-Mainar, Antoni, et al.
Publicado: (2012)

Use of metformin and vildagliptin for treatment of type 2 diabetes in the elderly
por: Sicras-Mainar, Antoni, et al.
Publicado: (2014)

Physicians’ and patients’ opinions on the use of generic drugs
por: Sicras-Mainar, Antoni, et al.
Publicado: (2012)

Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients
por: Sicras-Mainar, Antoni, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_sbq6df3j4s73u31o8gdk9ktgb9